Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Rapid, Point of Care Diagnostic for Malaria, highly sensitive for P. vivax, with species differentiation

Award Number: R44AI155116
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/06/2020
PERIOD OF PERFORMANCE END DATE: 07/31/2022

Group Awards By:

View Award Description

Rapid, Point of Care Diagnostic for Malaria, highly sensitive for P. vivax, with species differentiation - Project Summary/Abstract While significant progress has been made in reducing malaria prevalence and deaths, malaria elimination remains an extremely difficult goal. P. falciparum and P. vivax species of malaria parasites account for ~95% of all human malaria infections. P. falciparum is more virulent and has a higher incidence of adverse clinical outcomes, but P. vivax is more pervasive and widespread, often becoming the predominant species in regions moving toward elimination. These parasites follow a different course of disease and the treatment regimen differs, requiring an additional drug for P. vivax to eliminate a liver stage which causes disease relapse potentially years after infection. Current diagnostics have suboptimal accuracy, especially for P. vivax, as well as delayed turnaround times. Hemex aims to develop a one-minute, $1, point-of-care diagnostic that has a limit of detection for P. vivax >5x lower than RDTs. This diagnostic platform will also have the ability to differentiate between P. falciparum and P. vivax to allow for appropriate treatment. The proposed project advances our current rapid malaria detection device, which detects the presence of any malaria parasites in patients with >95% accuracy compared to microscopy. The new capability will be commercialized into a robust, portable, point-of-care product. It has the potential to greatly reduce malaria transmission and could substantially contribute towards reduction in human suffering as well as help to achieve malaria elimination.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2021	HEMEX HEALTH INC	4640 S MACADAM AVE STE 250	PORTLAND	OR	97239	MULTNOMAH	USA	Allergy and Infectious Diseases Research	000	3	10/24/2023	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $827,800 )
2021	2021	HEMEX HEALTH, INC.	4640 SW MACADAM AVE STE 250	PORTLAND	OR	97239	MULTNOMAH	USA	Allergy and Infectious Diseases Research	000	3	8/31/2021	NON-COMPETING CONTINUATION	$827,800
														Subtotal = $827,800

Issue Date FY: 2020 ( Subtotal = $840,440 )
2020	2020	HEMEX HEALTH, INC.	4640 SW MACADAM AVE STE 250	PORTLAND	OR	97239	MULTNOMAH	USA	Allergy and Infectious Diseases Research	000	2	8/6/2020	COMPETING CONTINUATION	$840,440
														Subtotal = $840,440

Grand Total All Awards = $1,668,240

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Rapid, Point of Care Diagnostic for Malaria, highly sensitive for P. vivax, with species differentiation

Award Number: R44AI155116

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/06/2020

PERIOD OF PERFORMANCE END DATE: 07/31/2022

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer